Drugs / GSK2339345
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01587716 | Apr → Jul 2012 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01494636 | Oct 2011 → Mar 2012 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01899768 | Nov 2013 → Oct 2014 | — | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2339345 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01899768 ↗ |
| Action | Inhibit | “GSK2339345 is a blocker of neuronal voltage gated sodium channels” NCT01494636 ↗ |
| Modality | Small molecule | — CHEMBL6068551 ↗ |
| Route | Other | “administered via an aqueous droplet inhaler” NCT01587716 ↗ |